Immunoprecise Antibodies (IPA)

• Market cap: $12.4M
• 1 day: -4.76%
• 5 days: 0.02%
• 1 month: 3.68%
• 3 months: -40.28%
• 6 months: -59.34%
• Year to date: -76.46%
• 1 year: -70.36%
• 5 years: -97.50%
• 10 years: -97.50%

About: ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.

Employees: 101

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.46% more ownership

Funds ownership: 6.33% [Q2] → 6.8% (+0.46%) [Q3]

5% less funds holding

Funds holding: 19 [Q2] → 18 (-1) [Q3]

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

28% less capital invested

Capital invested by funds: $1.69M [Q2] → $1.21M (-$476K) [Q3]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $7 1,650% upside
• Avg. target: $7 1,650% upside
• High target: $7 1,650% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 52 / 173 met price target

1,650% upside $7

Buy Maintained

11 Dec 2024